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ABSTRACT 
Background: A partially hydrolysed and dried product of pacific whiting fish is marketed as a 
health food supplement supporting ‘intestinal health’.  We examined whether it influenced the small 
intestinal damaging side effects of the non-steroidal anti-inflammatory drug, indomethacin.  
Methods: Eight human volunteers completed a double-blind, placebo-controlled, crossover 
protocol of clinically relevant dose of indomethacin (50 mg tds po for 5 days) with 7 days of fish 
hydrolysate or placebo starting 2 days prior to indomethacin. Changes in gut permeability were 
assessed using 5 h urinary lactulose: rhamnose (L/R) ratios.  
Results:  Fish hydrolysate given alone did not affect permeability. In the main study (N=8), baseline 
values were similar for both arms (0.28 +/- 0.05 and 0.35 +/- 0.07). Administration of indomethacin 
(+ placebo) caused a five-fold rise in L/R ratios (increasing to 1.54 +/- 0.35) whereas L/R ratios in 
the same subjects ingesting indomethacin + fish hydrolysate, was only 0.59 +/- 0.14, (p <0.01 vs. 
indomethacin alone). Dyspeptic symptoms occurred in 4/8 subjects taking indomethacin alone but 
0/8 when hydrolysate was co-administered.  
Conclusion: Natural bioactive products (nutriceuticals), such as this, may provide a novel approach 
to the prevention and treatment of NSAID-induced and other gastrointestinal injurious conditions. 
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INTRODUCTION 
There is currently a resurgence of interest in the use of natural bioactive products (‘nutriceuticals’) 
by the general public, with many healthy subjects and patients taking them for the prevention and 
treatment of multiple conditions, including gastrointestinal disorders1. Unfortunately, current 
evidence of the scientific validity of many of these traditional and commercial compounds is 
severely limited.   
 
One product of interest, that is already commercially available, is a fermented fish product derived 
from the controlled proteolytic yeast fermentation of pacific whiting (Merluccius productus). 
Fermentation is a commonly used process in the standard food industry as well as in the bioactive 
food (nutriceutical) field. Fermentation of foodstuffs has many effects, including partial degradation 
of protein constituents which, as well as potentially aiding absorption from the gut, may also 
influence its biological activity.  
 
Fish hydrolysate is claimed to be beneficial for a variety of gut conditions and we have previously 
shown it to be capable of stimulating proliferation and migration (restitution) of HT29 cells in 
vitro2. However, data examining its ability to influence gut integrity in human studies is severely 
limited. We chose to examine the potential activity of this fish hydrolysate against the damaging 
effects of the non-steroidal anti-inflammatory drug (NSAID) indomethacin as NSAIDs are some of 
the most widely prescribed group of drugs worldwide. Despite the undoubted efficacy of NSAIDs, 
side effects, including peptic ulceration and small intestinal injury are common and novel therapies 
are still required 3. 
 
We, therefore, performed a series of studies to analyse whether ingesting this fish hydrolysate 
product could influence the damaging effect of indomethacin on small intestinal integrity, as 
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assessed by following changes in permeability (leakiness) of the small intestine in a human clinical 
trial.   
 
MATERIALS & METHODS 
 
All chemicals were purchased from Sigma (Poole, Dorset) unless otherwise stated. 
 
Ethics 
Human studies were approved by appropriate regulatory authorities. Clinical trial REC reference 
number 05/Q0406/97. 
 
  
Hydrolysed fish protein concentrate 
The dried fish protein hydrolysate preparation studied, Seacure®, was donated by Proper Nutrition, 
Inc., Reading, PA, U.S.A (for details of preparation and constituents see ref 2). The fish protein 
hydrolysate contains 75-80% protein constituents (60% peptides and 40% amino acids and the 
major amino acid constituents are glutamine (approx. 14-16% of total), asparagine (10%) and lysine 
(10%) and 6-10% fish oils. 
 
Placebo 
A placebo was produced that was identical in colour and smell using rice flour with 1% sea 
cucumber. 
 
Clinical Study  
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Background to method  
Assessment of intestinal permeability by quantitating unmediated absorption of at least two sugars 
of different sizes provides a sensitive index of intestinal damage4. To maintain consistency with our 
previous studies (including osmolality), we administered a lactulose, rhamnose, mannitol mixture 
but again only present lactulose/rhamnose ratios for reasons previously described5. This is 
considered appropriate as this specific combination has been recommended for assessing 
enteropathy induced by NSAIDs6. 
 
Protocol 
Following an overnight fast, subjects emptied their bladders and then drank a standardised sugar 
solution containing lactulose 5g, mannitol 2g, and rhamnose 1g in a total of 450ml water (calculated 
osmolality 69 mOs).  Subjects were allowed unlimited intake of fluid after the first hour of the test 
to ensure adequate urine output.   The urine was collected and pooled over the next 5 hours and total 
volume recorded.  Aliquots were centrifuged briefly to remove gross debris and the supernatant 
frozen at -200C until later analysis. 
 
Analyses 
Analyses of sugar content within the urine were based on the methods and equipment used by our 
group previously5. The various sugars were separated using high pressure liquid chromatography 
(HPLC) and quantitated using a pulsed amphometric detector.  Using this technique, sugars are 
oxidised on the gold electrode at the working potential (P 0.05V), the current produced being a 
measure of the amount of sugar present in the sample7. 
 
Study protocols 
Preliminary studies:  
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A) To determine the reproducibility of results, a single individual performed permeability studies 
for 4 separate days (while not taking any test treatment or NSAIDs). These samples were assayed to 
determine intra-patient variation and gave a coefficient of variation of about 8%. In addition, a 
single sample was measured 6 times to determine intra-assay variation and gave a coefficient of 
variation of 5%.  These coefficients of variation were similar to those reported by us previously5. 
 
B) To examine whether fish hydrolysate influenced permeability under basal conditions, four 
subjects underwent an initial permeability assessment and then ingested fish hydrolysate for seven 
days with a further assessment on the final day.   
   
Main study:  
10 volunteers (25-40 yr., 5M, 5F) who were not taking NSAIDs or suffering from conditions likely 
to affect intestinal permeability e.g. coeliac disease or previous intestinal surgery, were entered into 
the study. Subjects abstained from alcohol consumption and ingestion of any NSAID, including 
aspirin, for one week prior to starting the study and throughout the remainder of the test period. 
Subjects were asked to record and report if they had any upper abdominal discomfort (‘dyspepsia’) 
prior to starting the protocol or during the two arms of the study. 
 
Each subject undertook a total of 6 permeability assessments (Fig 1). Each arm of the study 
comprised 3 collections on day -2, 0, and 7. For both arms, samples collected on days -2 and 0 were 
‘baseline’ analyses when the volunteer was not taking any test substance. After urine collection on 
day 0, volunteers took test substance comprising fish hydrolysate (1g) or placebo capsule three 
times daily for a week. Fish hydrolysate and placebo capsules were indistinguishable in terms of 
appearance and taste.  
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After the weeks course of test substance (day 7), the third urine collection for that arm of the study 
was completed.  Following a two-week washout period, each participant repeated the protocol with 
the other test capsule. The active and placebo capsule arms of the study were administered in 
random order.  In addition, in both arms of the study, for the last 5 days of the study (days 2-7) 
participants also received an NSAID (indomethacin 50mg tds, see Fig 1).  
 
Statistics 
All values are expressed as the mean+/-SEM. Two way ANOVA was used with presence of NSAID 
and presence of fish hydrolysate as factors. Where a significant effect was seen (p<0.05), individual 
comparisons were performed using t-tests based on the group means, residual and degrees of 
freedom obtained from the ANOVA, a method equivalent to repeated measures analyses.  
 
RESULTS 
 
Preliminary studies. 
In the four subjects who took fish hydrolysate for 7 days without taking an NSAID, there was no 
change in intestinal permeability (lactulose:rhamnose ratio was 0.53 +/- 0.13 before treatment vs.  
0.54 +/- 0.13 after treatment, Fig 2).  
 
Main study. 
Withdrawal: Two female volunteers (who started on the indomethacin plus placebo phase) were 
unable to tolerate the indomethacin due to onset of abdominal discomfort and withdrew from the 
study within 2 days of starting. They have, therefore, not been included in the analyses. The 
remaining 8 subjects completed the study.  
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Dyspepsia:  
At the beginning of the study, 7/8 subjects who completed the study had no dyspeptic (abdominal 
discomfort) symptoms and one subject had longstanding mild dyspepsia. There was no worsening 
or onset of symptoms in any of the 8 subjects when they took indomethacin plus fish hydrolysate. In 
contrast, 4/8 complained of onset or worsening of their dyspeptic symptoms when taking the 
indomethacin with placebo. 
 
Permeability 
Baseline permeability values were similar at the beginning of each study arm and at the first and 
second (baseline) assessments within a study arm (Fig 3).  Permeability increased about five-fold in 
response to indomethacin during the placebo arm (rising from 0.28 +/- 0.05, initial baseline value, 
to 1.54 +/- 0.35 at day 7, p < 0.01).  In contrast, when the subjects were also taking the fish 
hydrolysate, the rise in permeability caused by indomethacin was virtually completely abrogated in 
7/8 of the subjects and was markedly truncated in the 8th individual (rising from 0.35 +/- 0.07, initial 
baseline value, to 0.59 +/- 0.14 at day 7). Statistical analyses, using presence of fish hydrolysate and 
time as factors showed significant effects of time (i.e. indomethacin administration, F 2,42= 13.69, 
p < 0.0001), presence of fish hydrolysate (F1, 42= 4.34, p = 0.0433) and an interaction between the 
two. F2, 42= 6.27, p = 0.004). This showed that the rise in intestinal permeability caused by 
indomethacin was truncated by the presence of fish hydrolysate. Subsequent t-test comparisons 
based on mean square error of residual from ANOVA showed that permeability values at day 7 of 
both arms of study were significantly different (p < 0.01). The order in which placebo and fish 
hydrolysate was administered did not influence results (although numbers are too small to perform 
detailed statistical analysis).   
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DISCUSSION 
We have shown, for the first time, a commercially available fish hydrolysate preparation reduces the 
degree of small intestinal damage caused by the NSAID indomethacin in a pilot human clinical trial.  
 
Several methods are available to determine the degree of small intestinal injury induced by NSAIDs 
in humans, all of which have their drawbacks; Enteroscopy is an invasive procedure, [111In]- labelled 
white cells require radioactive exposure and measurement of the neutrophil marker, calprotectin in 
the stool is still at a relatively early stage of development8. Measurement of gut permeability is a 
safe, sensitive and simple investigation to perform but, as for all the other methods of assessment 
that do not involve direct visualisation, it is not readily equated to a score that uses visualisation, 
such as number of erosions9. Measurement of intestinal permeability has been used previously to 
assess the degree of small intestinal damage in patients with coeliac disease and Crohn's disease10 
and NSAID11 usage. The five-four rise in permeability found in the control arm of our main study is 
in keeping with our5,12, and others11, published works. 
Non-steroidal anti-inflammatory drugs are used worldwide but side effects such as dyspepsia, peptic 
ulceration and enteropathy are common and only partially relieved by acid suppressants. There is, 
therefore, a need for novel therapies. Indomethacin causes damage to the gastrointestinal tract by 
several mechanisms including reduction of mucosal prostaglandin levels, reduction of mucosal 
blood flow, stimulating neutrophil activation, and stimulating apoptosis13. It is likely that many of 
these mechanisms will be influenced by the numerous factors present in the fish hydrolysate. We 
have previously demonstrated pro-proliferative and pro-migratory (restitutive) activity of this fish 
hydrolysate product in vitro2, and the current studies expanded these in vitro results to show this 
products efficacy in a clinically relevant model. 
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The molecules responsible for the protective effects of the hydrolysate against indomethacin-
induced injury seen in the current study are incompletely defined. It is unlikely that this effect was 
due to the hydolysate influencing indomethacin adsorption as we have shown previously that the 
hydrolysate can reduce (systemically administered) indomethacin-induced gastric injury in rats 2. 
Our previous studies suggested glutamine within the fish hydrolysate played an important part, 
accounting for about 34 % of the pro-proliferative activity seen using an in vitro model and may 
also have contributed to antioxidant activity via stimulation of glutathione production.  Many of the 
amino acid constituents of the fish protein hydrolysate remain in the intact protein or partially 
cleaved form and it is also possible that these intact proteins have direct bioactivity as shown in 
partially digested bovine milk.14. The fish hydrolysate contains about 6-10% fish oils2. In addition to 
increasing migration15, and affecting prostaglandin production, these oils may contribute to anti-
apoptotic effects16. Further work is required, however, to determine in detail how these effects are 
mediated.   
 
Hundreds, if not thousands, of products are currently marketed as ‘health food supplements17.  72% 
of the American population use one or more health supplement products regularly and 57% 
considered that these therapies reduced their need for drugs and other medical therapies. This results 
in an annual turnover of £9 billion in the USA and £1.2 billion in the UK, with an 8% annual 
growth 17. The sources of these ‘natural’ products are diverse and include bacteria, plant, animal, 
and marine origins 1, 18.  Unfortunately, current evidence of the scientific validity of most of these 
traditional and commercial compounds is severely limited and the level of evidence used in support 
of their claims often falls well below that acceptable in the medical and scientific community.    
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The fish hydrolysate studied in this article is already marketed in the USA as an ‘over the counter’ 
health food supplement and, as with many of these products, its major marketing strategy is via 
patient validatory statements.  There have, however, been some limited scientific studies.  For 
example, Englender et al. reported that use of the fish protein hydrolysate, at a dosage of 3g per day 
for 60 days, reduced the symptoms of occasional diarrhoea and constipation, and alleviated 
bloating19.   
 
The positive effect in the current study is of particular interest as the doses of NSAID and fish 
hydrolysate used are at standard clinical dose and manufacturers recommended dose respectively. 
These results emphasise that the division between "food products" and "drugs", when considered in 
terms of biological activity (and concerns about potential safety aspects), is far from clear and 
products such as this should be considered as a "nutriceuticals" or functional foods. Although not 
directly relevant for this fish hydrolysate product, the distinction between ‘natural’ and ‘artificial’ is 
also blurred if a single compound is isolated and clinically used, even though it was from a ‘natural’ 
source initially.  
 
Further study of products based on fish hydrolysate for the prevention and treatment of other 
injurious conditions of the bowel, such as inflammatory bowel disease, necrotising enterocolitis and 
chemotherapy induced mucositis etc., where therapy is suboptimal and novel approaches are 
required, appear justified.   
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FIGURE LEGENDS 
 
Fig 1. Protocol for small bowel permeability trial. 
Healthy volunteers participated in a double-blinded randomised controlled cross-over protocol. 
Each arm comprised 3 urine collections (2 baseline). In each arm, volunteers took fish hydrolysate 
(1g) or placebo capsule three times daily for 7 days with indomethacin (50 mg three times daily) for 
the final 5 days. 
 
Fig 2.  Effect of fish hydrolysate on permeability under basal conditions.  
Four subjects underwent an initial permeability assessment and then ingested fish hydrolysate for 
seven days, without taking an NSAID, with a further assessment on the final day. Each line 
represents one individual’s permeability result expressed as lactulose/rhamnose ratio. There was no 
change in intestinal permeability in any of the subjects as result of taking fish hydrolysate. (Note 
same scale as in Fig 3.) 
 
 
Fig 3.  Effect of fish hydrolysate on indomethacin-induced permeability in a pilot clinical trial. 
8 individuals completed protocol shown in Fig 1. Each colour line represents one individual’s 
permeability result expressed as lactulose/rhamnose ratio. Black bars show mean values for each 
stage. Both arms were performed in random order. When taking placebo, volunteers had a five-fold 
increase in mean lactulose/rhamnose ratios in response to indomethacin administration (p < 0.01) 
whereas no significant increase was seen if fish hydrolysate was also being taken. 
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